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Essay
Operational Challenges in Large Clinical Trials:
Examples and Lessons Learned from the
Gambia Pneumococcal Vaccine Trial
Felicity T. Cutts
*
, Godwin Enwere, Syed M. A. Zaman, Fred G. Yallop
The requirements for Good Clinical
Practice (GCP) in clinical trials are well
documented [1], and ethical issues are
hotly debated [2]. Operational aspects
of trials, however, have received far
less attention [3], perhaps due to
restrictions on journal space for
detailing methods. In low resource
set t ings , however , large tr ia l s
often face many logistical and
organizational obstacles, and thus the
practical difﬁculties in running a trial
to GCP standards should not be
ignored. Here, we describe the
main operational challenges to a
randomized, double-blind, placebo-
controlled trial of the safety and
efﬁcacy of pneumococcal conjugate
vaccine among over 17,000 infants in
the Gambia. The trial began in August
2000, and after the magnitude of the
challenges were recognized, a new
senior principal investigator (FTC)
and project manager (FGY) were
recruited, taking up post in June 2001.
We summarize here the major lessons
learnt in trial implementation in a
resource-poor setting.
Overview of Trial Preparation
and Study Methods
The trial was conducted in Upper and
Central River Divisions of the Gambia,
covering an area of about 5,000 km2,
b i s e c t ed by the r i v e r Gamb ia .
Government mother-child health (MCH)
services are provided at 15 ﬁxed facilities,
the two largest being Bansang hospital in
the Central River Division and Basse
health centre in the Upper River
Division, and about 100 additional
outreach sites. The Medical Research
Council (MRC) main station is in Fajara,
380 km from Basse. The journey between
them took 5 hours in 2000 when the trial
began, and, due to deteriorating road
conditions, 9–10 hours by 2004 when it
ended.
Preparatory studies took over 12 years,
and included phase I [4] and phase II
vaccine trials [5], as well as baseline
studies of rates of disease and mortality
[6,7], and selection of the best design for
the phase III trial [8,9]. Toward the end of
this period, the study area was mapped
and a household numbering system was
devised. Communities and families were
informed about the forthcoming trial,
through drama performances in large
villages, radio spots, distribution of
ﬂyers , and community meetings .
Unfortunately, we did not evaluate
which method was most effective for
enhancing community support and
understanding of the trial.
The tria l was conducted as a
partnership between MRC and the
Gambia Government (GG), children
being recruited and vaccinated at GG
MCH clinics and referred through these
clinics for investigations. If MCH clinics
or outreach visits were cancelled, this
would jeopardise both public health
services and the research. The trial
funders and MRC therefore invested
greatly in infrastructure (capital
equipment and buildings, laboratories,
radiology facilities, cold chain, and
transport) for both Basse ﬁeld station
and GG health services.
The study methods, which followed
detailed standard operating procedures
(SOPs), have already been described in
detail [10]. The primary endpoint for the
trial was initially all-cause mortality but
was later changed to radiologically
conﬁrmed pneumonia, and secondary
endpoints were culture-conﬁrmed
invasive pneumococcal disease and
hospital admissions. Surveillance for
radiological pneumonia, invasive disease,
and serious adverse events took place 7
days a week at Basse and Bansang health
facilities, with referral of children from
outlying clinics over dirt roads and river
crossings, and each child was visited at
home every 3 months for demographic
surveillance.
The Importance of a Quality
Management Plan
The need for a quality management plan
is recognized as part of GCP, and we
developed a priority list of indicators for
quality assurance (Table 1). We aimed for
100% compliance with indicators relating
to following SOPs for recruitment,
storage of vaccines and placebo,
administration of either vaccine or
placebo (which were identical in
appearance and provided in numerically
coded vials) correctly according to the
code indicated in the randomization
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scheme, reporting and follow-up of
serious adverse events, and investigation
of children. A single error in any of these
areas was discussed immediately with the
relevant staff. For other indicators (e.g.,
dropout between ﬁrst and third doses of
vaccines; intervals between doses;
correlation between nurses and doctors’
clinical ﬁndings), we aimed for at least
95% comp l i anc e and r ev i ewed
performance at weekly staff meetings.
The Importance of On-Site
Supervision and Continuous
Feedback of Adherence to GCP
We monitored quality by continuous on-
site observation. We used TempTale cold
chain monitors and maximum-minimum
thermometers to monitor vaccine storage.
All completed case report forms (CRFs)
were checked by ﬁeld supervisors working
with the epidemiologist and principal
investigator (PI), with a spirit of
competition as to ability to spot
mistakes. We queried the data system
regularly to identify the number of
errors made by each person, and we
conducted random spot-checks of ﬁeld
work and home visits. The initial
procedure for supervisory rounds
stipulated that supervisors visit ﬁeld
worker s a t weekends (when no
recruitment or vaccination was in
progress) to collect the week’s CRFs, and
included few details on checking actual
ﬁeld activities. We changed this so that
supervision took place during clinic hours,
and trained supervisors to observe
practices and complete checklists that
included the key quality indicators. To
help ﬁeld workers spot their ownmistakes,
we conducted refresher training every 2–3
months, with written tests on the SOPs,
and on dummy completed CRFs on which
deliberate mistakes had been made (e.g.,
putting a date of vaccination before a date
of birth). We thus identiﬁed staff who had
difﬁculty in notic ing range and
consistency checks, and gave them
further on-the-job training. To improve
the clinical classiﬁcation of the sick child,
paediatricians worked with small groups
of three to four nurses at a time, each
completing a one-page ‘‘quality control’’
form to record respiratory rates and the
presence/absence of lower chest wall
indrawing simultaneously and compare
ﬁndings. We organized external quality
control for the key endpoints, all positive
pneumococcal cultures being conﬁrmed
in expert laboratories and a random
sample of radiographs being read by a
World Health Organization panel of
radiologists.
Feedback through on-the-spot
discussion of supervisors’ ﬁndings,
weekly staff meetings, and monthly
written reports to all staff and external
collaborators was done with the aim of
ensuring that everyone understood the
need to follow SOPs and meet GCP
requirements. We incorporated relevant
indicators into staff appraisals to further
demonstrate the importance of quality
assurance. We found that continuous
checking and feedback was required
throughout the study in order to
prevent standards from dropping. For
example, contamination of blood cultures
was high at the beginning of the trial but
was greatly reduced when we initiated
weekly reports from the laboratory to the
PI on the number of contaminated
samples, and memos from the PI to the
nurses who had taken those samples
supplemented by discussion at clinical
staff meetings each week. If we made this
feedback less frequently, contamination
rates tended to rise again.
Independent external trial monitors
visited every 4 months to review
regulatory and ethical aspects and check
source documents [1]. We made it very
obvious that all staff involved in the trial,
from PI to ﬁeld worker, were monitored.
This helped to create a ‘‘culture of
checking’’ that changed perceptions of
monitor ing from a threat to a
management tool and overcame initial
resistance to the periodic tests.
The Importance of Documenting
Roles and Responsibilities of
Collaborating Groups
Five interlocking groups of personnel
were involved in the trial: over 100 GG
MCH staff; 150 full-time trial ‘‘clinical’’
staff (doctors and nurses working in three
shifts to provide 24-hour cover and ﬁeld
workers doing home visits to the .17,000
children); 12 data staff; over 60 trial
‘‘support’’ staff (drivers, mechanics,
administrators, clerks, cleaners, cooks,
etc . ) , and external col laborating
scientists and administrative staff based
in MRC Fajara and overseas. Multiple
coordination mechanisms were needed,
ranging from frequent informal contacts
in-person at the local level and by
telephone/email internationally, to
formal, minuted working groups and
steering committees. Close collaboration
between the trial senior management and
GG health teams was important to avoid
cancellation of outreach clinics that might
otherwise have occurred due, for example,
to shortage of transport or conﬂicting
activities. We felt that collaboration would
have been further enhanced had
memoranda of understanding been
written before the trial began; in their
absence, it was sometimes difﬁcult to
demarcate the requirements for the
research project and the wide-ranging
needs of the public health system.
........................................................................................................................
Table 1. Major Indicators Used for Quality Assurance
Activity Area Indicator
Recruitment All registration forms have attached signed consent form, in appropriate
local language.
Study product No stock-outs of study product.
All sites store study product at appropriate temperatures.
Utilization and accountability follows SOPs.
Vaccination All children receive correct code of study product (vaccine or placebo).
.95% receive all three doses.
.95% have correct intervals (28 d) between doses.
Median age at each dose as close as possible to recommended
age of 6, 10, 14 wk.
Demographic surveillance % children ‘‘absent’’ or ‘‘travelling’’ (extreme values led to more
intensive spot-checks of field work).
Clinical All children investigated according to SOPs.
Nurse counts respiratory rates to within 63 breaths per minute
of paediatrician’s count .95% of the time.
Nurse correctly classifies lower chest wall indrawing .95% of instances.
Nurse correctly classifies children as meeting World Health Organization
criteria for lower respiratory tract infection .95% of instances.
Laboratory .95% of samples reaching laboratory within 3 h of collection.
No blood cultures to be contaminated.
All culture results confirmed by external quality control.
Radiology .95% of radiographs classified as ‘‘satisfactory’’ according to the
criteria of the World Health Organization radiology working group.
Serious adverse events (SAEs) All SAEs faxed to Data Safety Monitor and sponsor within 48 hours.
All SAEs followed up to determine outcome.
DOI: 10.1371/journal.pctr.0010016.t001..
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The Importance of Transparent
Human Resource Management
Procedures
Human r e s ou r c e t r a i n i n g and
management took up a large proportion
of time of both the PI (who focussed on
quality assurance, management of clinical
staff, and collaboration with external
scientists) and project manager (who
managed all support staff and liaised
with external administrative and
management personnel).
MRC’s written, transparent policies on
recruitment, career development,
appr a i s a l s y s t ems , d i s c i p l i n a r y
procedures, leave entitlements, health
and safety, etc., helped to guide
supervisors and managers (for example,
by showing what procedures need to be
documented in order for appropriate
decisions to be made) and to set limits
for negotiations between staff and
managers. We revised job descriptions to
ensure that they were realistic, clear, and
achievable. For example, initially some
job descriptions for different posts
overlapped, creating the potential either
for unhealthy competition or for each
person thinking someone else was
responsible for a particular task,
whereas others were too broad to be
feasible to complete. Other actions to
improve staff performance included
mentoring, rotating personnel between
sites, and training. This ranged from
distance-based learning undergraduate
and postgraduate degree programmes
and short courses inside and outside the
Gambia, to literacy classes, basic
computing, and in-service training and
accreditation programmes for all
categories of staff.
The Importance of Adequate
Planning for Trial
Implementation
Planning for a trial requires that baseline
situation assessments be conducted of the
r e s o u r c e s a v a i l a b l e f o r t r i a l
implementation. Given the typically long
delay between planning a trial and
obtaining the funding, clearances, and
vaccine to begin the trial, and the time
then required for recruitment and follow-
up, these assessments need to predict the
needs over the whole life of the trial. In
our trial, adequate plans were made for
purchasing cold chain equipment, but we
faced substantial problems with transport
and maintenance and other risks to
successful completion of the trial.
Transport. At the trial outset, ﬁve
four-wheel drive vehicles were given to
the national and divisional government
health teams to assist in supervision of
MCH activities. In a rapid assessment of
the MCH infrastructure in the study area
in mid-2001, however, we found that most
clinics had severe transport problems,
because support to the front-line health
services had not been planned. The trial
therefore assigned vehicles to clinics to
take MCH teams on outreach and to refer
ill children to Basse or Bansang, and
assisted in the maintenance of GG as well
as trial vehicles. This further stretched
the ability of our maintenance team to
meet demands, and increased the need
for close coordination between partners
to prioritize vehicles and equipment for
repairs. It also highlighted the need for
plans to take into account the expected
duration of a trial and realistic working
life of vehicles in harsh conditions, and
budget for replacement costs of essential
items, and for written memoranda of
understanding to be developed to help
to manage expectations.
Maintenance. Because radiological
pneumonia was the primary endpoint,
having access to radiology equipment
was critical. The trial had refurbished
radiology rooms and supplied new dryers
and developing tanks, as well as bought
two state-of-the-art radiology machines
for Bansang hospital and Basse health
centre. It proved difﬁcult to bring
engineers to maintain these in a timely
way, and in 2002, we bought two portable
machines for a fraction of the cost, which
were more robust and produced good
quality ﬁlms. We maintained transport,
equipment, and the all-important
generators that were the source of power
for the radiology equipment, laboratories,
divisional cold stores, Basse health centre,
and ﬁeld station, and little assistance was
available in this remote location. The
engineering background of the project
manager was therefore frequently called
on, and substantial external support was
required. Detailed inventories of
equipment and ﬁxed assets were
developed, and use of stocks (e.g., spare
parts, fuel, drugs) was computerized and
monitored regularly to avoid stock-outs of
critical items and reduce excessive use.
Risk management. No matter how
good the planning and management of
trials, risks will remain. Some of the
‘‘unforeseen’’ risks are so common in
low-resource settings that they should be
expected. Those that we faced included
currency devaluation, natural disasters
(ﬂooding of Basse town and ﬁeld station)
(see Figure 1), health and safety hazards
such as road trafﬁc accidents, national
campaigns (on different occasions for
mea s l e s , men ing i t i s and po l i o
vaccination), and deterioration in access
to the study site. We needed to liaise
closely with national, regional, and
international authorities and identify
local and external sources of support to
reduce disruption of activities to a
minimum.
Conclusions and Lessons
Learned
There are many operational challenges in
running large ﬁeld trials and strong
leadership and teamwork is essential to
confront them. We summarise the main
ways to improve trial management in Box
1. To train personnel and generate the
team spirit to implement a large trial to
GCP in difﬁcult ﬁeld conditions, a senior
principal investigator needs to be
permanently on-site to organize quality
a s surance and ensure e f f ec t i ve
communication between all the groups
involved, and a full-time, senior project
manager is needed to organize and
oversee all the support services needed
to keep the trial running. We found other
factors helping to achieve a high level of
motivation and team spirit were the
appointment of staff with appropriate
and complementary skills, substantial
training, objective and transparent
monitoring procedures, feedback to
each staff member that their work was
important for the trial and for society,
and recognition of their achievements by
both senior staff and external advisory
committees. Training is not just
important at the start of a trial, it is a
continuous need, because staff change
and existing staff need constant
motivation and support. We recommend
the frequent use of written tests to assess
knowledge of SOPs and ability to spot
DOI: 10.1371/journal.pctr.0010016.g001
Figure 1. Main Gate into the MRC Field Station
during the Floods
Photo by Fred Yallop.
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mistakes on CRFs, in addition to
observation of ongoing practices. We
also recommend setting out detailed and
appropriate job descriptions, and
including measurable performance
ob j e c t i v e s i n s t a f f a pp r a i s a l s .
Experienced staff should act as mentors
for new staff, and staff rotation between
areas of work and locations can help to
avoid boredom or a feeling of isolation of
staff working in the more remote
locations. A comprehensive quality
assurance plan is vital and a mixture of
internal and external monitoring and
auditing is important. Visits from
external monitors should be used not
only for GCP audit but also to educate all
staff of the reasons for, and importance
of, quality control.
Multiple stakeholders are likely to be
involved and may pool resources to run
large trials. Memoranda of understanding
should be written at the outset, to
de l ineate c lear ly the roles and
responsibilities of different partners, as
well as the resources provided to or by
each partner and their disposition at the
end of the trial. The resources available at
the study site should be reviewed
carefully to determine the need for
external specialist advice and identify
appropriate sources for this. Aspects
likely to require external support when
a trial is run in a remote setting include
power supplies, communications, data
management (we will describe this in a
separate report), cold chain, health and
safety, and security.
The scientiﬁc objectives of a trial need
to be translated into a detailed project
development plan that outlines the key
steps, activities, milestones, and critical
path to ensure that trial implementation
proceeds as planned. Tools such as MS
Project are useful to track the multiple
interlocking activities and ensure that
milestones are reached on time.
Training on effective project planning
and evaluation in biomedical research
and the use of such tools are now
available via the Special Programme for
Research andTraining in Tropical Diseases
(e.g., see www.who.int/tdr/publications/
publications/training_manual.htm).
Existing clinical trial and data
management guidelines should be
expanded to incorporate monitoring of
these areas and of accounting and
budgetary management and control
procedures. The management challenges
in implementing large trials in resource-
p o o r s e t t i n g s s h o u l d n o t b e
underestimated and budgets must
include adequate investment to meet
these challenges. “
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Box 1. Ways to Improve the Operation of Large Phase III Field Trials
1. All senior staff to be on-site, including PI and project manager, who must create strong team
spirit.
2. Establish clear SOPs, define process indicators, and set up internal and external monitoring
systems for clinical, data, and support procedures.
3. Document roles and responsibilities of collaborating groups through memoranda of
understanding.
4. Define tasks clearly and realistically, assign responsibility and accountability, and make sure
people know what to do and have the skills and support to do it.
5. Make plans based on situation assessments conducted by a team including experienced
managers, including risk management plans.
6. Identify the appropriate resources for the trial and for partners involved in implementing the
trial.
7. Take into account the operational life of transport and equipment in the relevant field
conditions and budget for replacement costs of essential items.
8. Make adequate arrangements for maintenance, including skilled staff, workshops with
appropriate space and safety arrangements, and timely external support as required.
9. Monitor everything closely, anticipate problems, and react early.
10. Check, check, check, check, check. . .and check again.
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